Alison C MacKinnon Selected Research

substance P (6-11)

1/2009

Targeting V1A-vasopressin receptors with [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alison C MacKinnon Research Topics

Disease

2	Neoplasms (Cancer) 01/2019 - 01/2009
1	Idiopathic Pulmonary Fibrosis 01/2021
1	Adenocarcinoma of Lung 01/2019
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2019
1	Neoplasm Metastasis (Metastasis) 01/2019
1	Stable Angina 12/2014
1	ST Elevation Myocardial Infarction 12/2014
1	Heart Failure 12/2014
1	Myocardial Infarction 12/2014
1	Pain (Aches) 12/2014
1	Atherosclerosis 06/2013
1	Fibrosis (Cirrhosis) 09/2011
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 09/2011
1	Lung Neoplasms (Lung Cancer) 01/2010
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2009

Drug/Important Bio-Agent (IBA)

4	Galectin 3 (LGALS3)IBA 01/2021 - 06/2013
2	LectinsIBA 01/2021 - 01/2019
1	Galectins (Galectin)IBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2019
1	ApolipoproteinsIBA 06/2013
1	CollagenIBA 09/2011
1	Biomarkers (Surrogate Marker)IBA 09/2011
1	Bleomycin (Blenoxane)FDA LinkGeneric 09/2011
1	Pharmaceutical PreparationsIBA 01/2010
1	Biological ProductsIBA 01/2010
1	Gastrin-Releasing PeptideIBA 01/2009
1	substance P (6-11)IBA 01/2009
1	Arginine Vasopressin (Argipressin)IBA 01/2009

Therapy/Procedure

3	Therapeutics 01/2019 - 01/2009
1	Oral Administration 01/2019